Immunotherapy of type 1 diabetes - How to rationally prioritize combination therapies in T1D

International Immunopharmacology

Volumn 10, Issue 12, 2010, Pages 1491-1495

  Boettler, Tobias ^a   Von Herrath, Matthias ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Combination therapy; Immunotherapy; Type 1 diabetes

Indexed keywords

CD3 ANTIBODY; DACLIZUMAB; EPIDERMAL GROWTH FACTOR; GASTRIN; GLUTAMATE DECARBOXYLASE 65; INSULIN; LANSOPRAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SITAGLIPTIN; THYMOCYTE ANTIBODY;

ANAPHYLAXIS; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHADENOPATHY; LYMPHOCYTE DEPLETION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INSULIN-SECRETING CELLS;

EID: 78649983200     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.07.008     Document Type: Article

References (39)

1. E.E. Baschal, and G.S. Eisenbarth Extreme genetic risk for type 1A diabetes in the post-genome era J Autoimmun 31 1 2008 1 6
2. M. von Herrath, S. Sanda, and K. Herold Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 7 12 2007 988 994
3. C.M. Filippi Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice J Clin Invest 119 6 2009 1515 1523
4. C.M. Filippi, and M.G. von Herrath Viral trigger for type 1 diabetes: pros and cons Diabetes 57 11 2008 2863 2871
5. M. Rewers, and P. Gottlieb Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future Diab Care 32 10 2009 1769 1782
6. D. Bresson, and M. von Herrath Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside Diab Care 32 10 2009 1753 1768
7. T. Nir, D.A. Melton, and Y. Dor Recovery from diabetes in mice by beta cell regeneration J Clin Invest 117 9 2007 2553 2561
8. D.V. Serreze B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice J Exp Med 184 5 1996 2049 2053
9. M.D. Pescovitz Rituximab, B-lymphocyte depletion, and preservation of beta-cell function N Engl J Med 361 22 2009 2143 2152
10. L. Chatenoud Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice Proc Natl Acad Sci USA 91 1 1994 123 127
11. K.C. Herold Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 346 22 2002 1692 1698
12. K.C. Herold A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes Diabetes 54 6 2005 1763 1769
13. B. Keymeulen Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes N Engl J Med 352 25 2005 2598 2608 (Pubitemid 41007846)
14. L. Chatenoud, and J.A. Bluestone CD3-specific antibodies: a portal to the treatment of autoimmunity Nat Rev Immunol 7 8 2007 622 632
15. F. Saudek Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset Rev Diabet Stud 1 2 2004 80 88
16. N. Shehadeh Effect of adjuvant therapy on development of diabetes in mouse and man Lancet 343 8899 1994 706 707
17. L. Ban Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism Proc Natl Acad Sci USA 105 36 2008 13644 13649
18. L. Mastrandrea Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study Diab Care 32 7 2009 1244 1249
19. M. Arnush IL-1 produced and released endogenously within human islets inhibits beta cell function J Clin Invest 102 3 1998 516 526
20. C.M. Larsen Interleukin-1-receptor antagonist in type 2 diabetes mellitus N Engl J Med 356 15 2007 1517 1526
21. S. Sanda T.128. Short-term administration of anakinra does not appear to affect stimulated C-peptide responses acutely in patients with type 1 diabetes Clin Immunol 131 Supplement 1 2009 S89
22. N. Solvason Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites J Immunol 181 12 2008 8298 8307
23. C. Ploix Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes Diabetes 47 1 1998 39 44
24. D.G. Karounos, J.S. Bryson, and D.A. Cohen Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice J Clin Invest 100 6 1997 1344 1348
25. D.G. Alleva Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope Scand J Immunol 63 1 2006 59 69
26. S.L. Thrower Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study Clin Exp Immunol 155 2 2009 156 165
27. J. Ludvigsson GAD treatment and insulin secretion in recent-onset type 1 diabetes N Engl J Med 359 18 2008 1909 1920
28. L. Bouwens, and I. Rooman Regulation of pancreatic beta-cell mass Physiol Rev 85 4 2005 1255 1270
29. P.C. Butler The replication of beta cells in normal physiology, in disease and for therapy Nat Clin Pract Endocrinol Metab 3 11 2007 758 768
30. G. Xu Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 12 1999 2270 2276
31. O.G. Kolterman Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 88 7 2003 3082 3089
32. D.M. Harlan Current advances and travails in islet transplantation Diabetes 58 10 2009 2175 2184
33. S.H. Lee Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies Transplantation 87 7 2009 983 991
34. A.F. Tarantal, C.C. Lee, and P. Itkin-Ansari Real-time bioluminescence imaging of macroencapsulated fibroblasts reveals allograft protection in rhesus monkeys (Macaca mulatta) Transplantation 88 1 2009 38 41
35. B.K. Kleinschmidt-DeMasters, and K.L. Tyler Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis N Engl J Med 353 4 2005 369 374
36. K.I. Rother Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes Diab Care 32 12 2009 2251 2257
37. D. Bresson Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes Mol Ther 2009
38. D. Bresson Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs J Clin Invest 116 5 2006 1371 1381
39. N.A. Sherry Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells Endocrinology 148 11 2007 5136 5144